Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Novo Nordib A / S Orted CEO Lars Frugenaard Jorgensen, because the presenter fights the growing competition weighing in the stock price, which is fighting increasing competition for the treatment of obesity.
The Danish company said Jorgensen was divided by a mutual agreement with the Board of the Board, although he will continue to “a while to support a smooth passage to the new management.” A new leader’s search began, the company said in a statement on Friday.
The transition has fallen by about 2% in cases where the matches of 53% reduction in the stock price of the company’s share price, new weight loss medications and eli Lilly & Co.
“Taking into account the latest market problems, declining stock prices and the Novo Nordisk Foundation of the Novo Nordisk Foundation and Lars Fruganard Jorgensen, the joint company and shareholders have concerned about the best interest in the company and shareholders,” he said.
Foundation, a leading philanthropist group, said Novo, “said Novo with the” essence of the accelerated CEO inheritance “with the board of Nova.
Novo, Wegovy and sister medicine for diabetes came to the market with the ozemptic, but the Danish company Lilly closed the market share. Zepbound in his opponent now has a leading in obesity recipes and the Lilly diabetes version of the drugs, Mounjaro, BMO continues to hold along with Ozempt next to the capital markets.
Jorgensen has been with Novo since 1991, and in January 2017, the company is three times more during market capitalization.
This story was first displayed Fortune.com
